LEPR and breast carcinoma: Furthermore, the data obtained emphasizes the possibility of blocking the leptin/leptin receptor axis, as an adjuvant therapy in cats with luminal B and triple-negative mammary carcinoma subtypes, as reported for breast cancer patients (42, 44–46).